Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42

Related Articles by Review for PubMed (Select 19932784)

1.

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Lévy N, Maillard L, Barragan P, Dignat-George F, Camoin-Jau L, Bonello L.

Am J Cardiol. 2009 Dec 1;104(11):1511-5. doi: 10.1016/j.amjcard.2009.07.015.

PMID:
19932784
2.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
3.

Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL.

Am Heart J. 2010 Sep;160(3):543-51. doi: 10.1016/j.ahj.2010.06.004. Review.

PMID:
20826265
4.

Genetic variability in response to clopidogrel therapy and its clinical implications.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K.

Thromb Haemost. 2011 May;105 Suppl 1:S55-9. doi: 10.1160/THS10-11-0747. Epub 2011 Apr 11. Review.

PMID:
21479337
5.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiĭ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
6.

Factors associated with clopidogrel nonresponsiveness.

Momary KM, Dorsch MP.

Future Cardiol. 2010 Mar;6(2):195-210. doi: 10.2217/fca.10.1. Review.

PMID:
20230261
7.

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

Ford NF.

J Clin Pharmacol. 2009 May;49(5):506-12. doi: 10.1177/0091270009332433. Epub 2009 Feb 26. Review.

PMID:
19246723
8.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
9.

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.

Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I.

Am J Cardiol. 2007 Oct 15;100(8):1199-206. Epub 2007 Jul 30. Review.

PMID:
17920357
10.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Epub 2011 Dec 30. Review.

PMID:
22207144
11.

Genetic determinants of on-clopidogrel high platelet reactivity.

Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R.

Platelets. 2011;22(6):399-407. doi: 10.3109/09537104.2011.579648. Epub 2011 May 31. Review.

PMID:
21627411
12.

Clinical impact of genetically determined platelet reactivity.

Laine M, Arméro S, Peyrol M, Sbragia P, Thuny F, Paganelli F, Bonello L.

J Cardiovasc Transl Res. 2013 Jun;6(3):398-403. doi: 10.1007/s12265-012-9421-4. Epub 2012 Nov 13. Review.

PMID:
23149816
13.

Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.

Wong YW, Prakash R, Chew DP.

Curr Opin Cardiol. 2010 Jul;25(4):305-11. doi: 10.1097/HCO.0b013e328339f1aa. Review.

PMID:
20421791
14.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

15.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
16.

Personalized antiplatelet therapy: review of the latest clinical evidence.

Camilleri E, Jacquin L, Paganelli F, Bonello L.

Curr Cardiol Rep. 2011 Aug;13(4):296-302. doi: 10.1007/s11886-011-0194-1. Review.

PMID:
21594586
17.

Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?

Gurbel PA, Roe MT, Jakubowski JA, Shah S, Erlinge D, Goodman SG, Huber K, Chan MY, Cornel JH, Tantry US, Ohman EM.

Thromb Haemost. 2012 Jul;108(1):12-20. doi: 10.1160/TH12-01-0039. Epub 2012 May 25. Review.

PMID:
22627684
18.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
19.

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

Giusti B, Gori AM, Marcucci R, Abbate R.

Expert Opin Drug Metab Toxicol. 2010 Apr;6(4):393-407. doi: 10.1517/17425251003598878. Review.

PMID:
20163283
20.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk